Patient characteristics and results
| Characteristic . | Value . |
|---|---|
| No. of patients | 162 |
| Median age, y (range) | 56 (32-73) |
| Sex of patient, n | |
| Male | 96 |
| Female | 66 |
| Sex of donor, n | |
| Male | 102 |
| Female | 60 |
| Myelofibrosis, n | |
| Primary | 105 |
| Post-PV/ET | 57 |
| Median time, mo (range), for diagnosis to SCT | 50 (3-360) |
| Risk profile according to Lille score, n | |
| Low | 35 |
| Intermediate | 91 |
| High | 32 |
| Unknown | 4 |
| Risk profile according to Cervantes score, n | |
| Low | 46 |
| High | 110 |
| Unknown | 6 |
| Risk profile according to IPSS, n | |
| Low | 4 |
| Intermediate-1 | 26 |
| Intermediate-2 | 52 |
| High | 70 |
| Unknown | 10 |
| JAK2 V617F mutation status, n | |
| Positive | 95 |
| Negative | 44 |
| Unknown | 23 |
| Cytogenetics, n | |
| Favorable | 6 |
| Normal | 53 |
| Other | 23 |
| Unfavorable | 17 |
| Unknown | 63 |
| Transfusion dependency, n | |
| Not transfusion-dependent | 65 |
| Transfusion-dependent | 86 |
| Unknown | 11 |
| Splenectomy, n | 20 |
| HLA matching (10/10 alleles), n | |
| Matched | 129 |
| Mismatched | 33 |
| HLA identical sibling, n | 46 |
| Unrelated donor, n | 116 |
| Median no. (range) of CD34+ infused stem cells per kg BW | 6.9 × 106 (0.7-21.7 × 106) |
| CMV serostatus of recipients, n | |
| Positive | 83 |
| Negative | 72 |
| Unknown | 7 |
| Conditioning, n | |
| Busulfan/fludarabine based | 156 |
| Treosulfan/fludarabine | 6 |
| Primary graft failure, n (%) | 9 (6.5) |
| Median time, d (range), to leukocyte engraftment (NC > 1.0 × 109/L) | 17 (9-84) |
| Acute GVDH (n = 155), n (%) | |
| Grade 0-I | 130 (84) |
| Grade II-IV | 25 (16) |
| Grade III-IV | 9 (6) |
| Chronic GVHD (n = 136), n (%) | |
| Limited | 24 (18) |
| Extensive | 27 (20) |
| Characteristic . | Value . |
|---|---|
| No. of patients | 162 |
| Median age, y (range) | 56 (32-73) |
| Sex of patient, n | |
| Male | 96 |
| Female | 66 |
| Sex of donor, n | |
| Male | 102 |
| Female | 60 |
| Myelofibrosis, n | |
| Primary | 105 |
| Post-PV/ET | 57 |
| Median time, mo (range), for diagnosis to SCT | 50 (3-360) |
| Risk profile according to Lille score, n | |
| Low | 35 |
| Intermediate | 91 |
| High | 32 |
| Unknown | 4 |
| Risk profile according to Cervantes score, n | |
| Low | 46 |
| High | 110 |
| Unknown | 6 |
| Risk profile according to IPSS, n | |
| Low | 4 |
| Intermediate-1 | 26 |
| Intermediate-2 | 52 |
| High | 70 |
| Unknown | 10 |
| JAK2 V617F mutation status, n | |
| Positive | 95 |
| Negative | 44 |
| Unknown | 23 |
| Cytogenetics, n | |
| Favorable | 6 |
| Normal | 53 |
| Other | 23 |
| Unfavorable | 17 |
| Unknown | 63 |
| Transfusion dependency, n | |
| Not transfusion-dependent | 65 |
| Transfusion-dependent | 86 |
| Unknown | 11 |
| Splenectomy, n | 20 |
| HLA matching (10/10 alleles), n | |
| Matched | 129 |
| Mismatched | 33 |
| HLA identical sibling, n | 46 |
| Unrelated donor, n | 116 |
| Median no. (range) of CD34+ infused stem cells per kg BW | 6.9 × 106 (0.7-21.7 × 106) |
| CMV serostatus of recipients, n | |
| Positive | 83 |
| Negative | 72 |
| Unknown | 7 |
| Conditioning, n | |
| Busulfan/fludarabine based | 156 |
| Treosulfan/fludarabine | 6 |
| Primary graft failure, n (%) | 9 (6.5) |
| Median time, d (range), to leukocyte engraftment (NC > 1.0 × 109/L) | 17 (9-84) |
| Acute GVDH (n = 155), n (%) | |
| Grade 0-I | 130 (84) |
| Grade II-IV | 25 (16) |
| Grade III-IV | 9 (6) |
| Chronic GVHD (n = 136), n (%) | |
| Limited | 24 (18) |
| Extensive | 27 (20) |
BW indicates body weight; CMV, cytomegalovirus; NC, nuclear cells; and GVHD, graft-versus-host disease.